Ellevest, Inc. Bei Gene, Ltd. Transaction History

Ellevest, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$121.11 - $216.05 $1,453 - $2,592	-12 Closed	0 $0
Q1 2022 Apr 19, 2022	SELL	$146.52 - $269.56 $7,179 - $13,208	-49 Reduced 80.33%	12 $2,000
Q4 2021 Jan 24, 2022	SELL	$248.56 - $389.34 $3,976 - $6,229	-16 Reduced 20.78%	61 $17,000
Q3 2021 Oct 19, 2021	SELL	$249.6 - $403.14 $1,996 - $3,225	-8 Reduced 9.41%	77 $28,000
Q1 2021 May 03, 2021	SELL	$260.64 - $382.12 $1,042 - $1,528	-4 Reduced 4.49%	85 $30,000
Q4 2020 Feb 04, 2021	BUY	$221.31 - $316.61 $16,598 - $23,745	75 Added 535.71%	89 $23,000
Q3 2020 Oct 26, 2020	BUY	$189.18 - $286.44 $2,648 - $4,010	14 New	14 $4,000
Q2 2020 Jul 06, 2020	SELL	$123.9 - $195.41 $619 - $977	-5 Closed	0 $0
Q1 2020 Apr 13, 2020	BUY	$121.84 - $173.19 $609 - $865	5 New	5 $1,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.